Proteomics International Laboratories Ltd (PIQ.AX) Novel OxiDx Test Detects Muscle Damage in Elite Athletes
- 66
Perth, Australia (ABN Newswire) - Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in precision diagnostics, is pleased to announce that its subsidiary OxiDx Pty Ltd, has published groundbreaking results demonstrating the unique OxiDx test for oxidative stress can identify muscle damage and assess recovery in elite marathon runners.
- Groundbreaking results demonstrate the OxiDx test can identify and assess recovery from exercise-induced muscle damage in elite marathon runners
- New results show OxiDx's novel technology offers a simple solution for monitoring levels of muscle damage using an easy-to-use fingerprick blood test
- Results are a significant milestone proving the OxiDx test can be used to monitor athletic performance
- Results published in the peer-reviewed journal Physiological Reports
- Oxidative stress has been implicated in many disease and injury states - target applications include high-performance athletes and the horse racing industry
- In professional sports muscle injuries account for up to 55% of all injuries - $1.2 billion was spent in Australia alone on treating potentially avoidable sports injuries in 2023
The study addresses a significant gap in the field of sports science, focusing on the lack of sensitive biomarkers for exercise-induced muscle damage. In professional sports, muscle injuries are the most frequent cause of incapacity, accounting for up to 55% of all injuries. Similarly, in the horse racing industry, 85% of thoroughbreds suffer at least one injury during their first 2-3 years of their racing career. In 2023, $1.2 billion was spent on treating potentially avoidable sports injuries in Australia.
Proteomics International Managing Director Dr Richard Lipscombe said, "these results could literally be a game changer for sports medicine - they have implications for all high-performance athletes, from footballers to horse racing. If we can detect unseen muscle damage, then athletes can adjust their training regime to avoid more serious injury."
Marathon running causes extensive muscle damage, known as exercise-induced muscle damage (EIMD), which can impair performance and increase injury risk if recovery is incomplete. This study, published in the international peer-reviewed journal Physiological Reports, highlighted the ability of the OxiDx oxidative stress test as a novel diagnostic for monitoring this recovery. Levels of oxidative stress peaked 48 hours post-marathon and remained elevated for up to five days, correlating with traditional muscle damage indicators like reduced muscle force, increased soreness, and elevated creatine kinase.
Group data across the 20 participants indicated recovery by day six, however, individual variability was significant, with some runners showing prolonged recovery times. This variability emphasises the importance of individualised recovery monitoring to prevent premature training resumption. OxiDx's diagnostic sensitivity to recovery processes surpasses traditional markers by offering athletes and coaches a novel reliable tool for optimising post-marathon recovery and enhancing performance.
The world-first, patented OxiDx technology measures levels of muscle damage using a simple finger-prick blood sample to detect protein biomarkers in the blood. There is no equivalent test on the market. This successful study is a significant milestone in the commercialisation of the OxiDx test which is targeted for an Australian launch in H1 CY25.
About OxiDx
OxiDx Pty Ltd (Perth, Western Australia) is a 66 per cent owned subsidiary of Proteomics International.
OxiDx is commercialising technology for measuring oxidative stress developed in collaboration with The University of Western Australia. OxiDx uses next generation diagnostics technology, moving beyond measuring protein concentrations to detect subtle changes in protein structures known as posttranslational modifications or 'decorations' that reside on the surface of a protein. The patented OxiDx platform technology measures systemic oxidative stress in a fingerpick blood sample by using a sensitive ratiometric method to detect protein biomarkers in the blood. Samples can be collected in the home, clinic or on the field with high specificity to provide a comprehensive solution for monitoring oxidative stress levels.
Oxidative stress is implicated in over 70 health conditions with a person's levels often reflective of health and fitness. The ability to measure oxidative stress has broad application across multiple markets, from an athletic monitoring tool for competition preparedness and injury reduction in professional sports and horse racing industries, to a monitoring tool for health and wellbeing, including in primary industries such as stock production. It could also serve as a complementary diagnostic (CDx) test for assessing treatment efficacy and precision medicine by enabling personalised dosing in clinical trials.
*To view the Summary of Study, please visit:
https://abnnewswire.net/lnk/1WMJ4XK9
- Groundbreaking results demonstrate the OxiDx test can identify and assess recovery from exercise-induced muscle damage in elite marathon runners
- New results show OxiDx's novel technology offers a simple solution for monitoring levels of muscle damage using an easy-to-use fingerprick blood test
- Results are a significant milestone proving the OxiDx test can be used to monitor athletic performance
- Results published in the peer-reviewed journal Physiological Reports
- Oxidative stress has been implicated in many disease and injury states - target applications include high-performance athletes and the horse racing industry
- In professional sports muscle injuries account for up to 55% of all injuries - $1.2 billion was spent in Australia alone on treating potentially avoidable sports injuries in 2023
The study addresses a significant gap in the field of sports science, focusing on the lack of sensitive biomarkers for exercise-induced muscle damage. In professional sports, muscle injuries are the most frequent cause of incapacity, accounting for up to 55% of all injuries. Similarly, in the horse racing industry, 85% of thoroughbreds suffer at least one injury during their first 2-3 years of their racing career. In 2023, $1.2 billion was spent on treating potentially avoidable sports injuries in Australia.
Proteomics International Managing Director Dr Richard Lipscombe said, "these results could literally be a game changer for sports medicine - they have implications for all high-performance athletes, from footballers to horse racing. If we can detect unseen muscle damage, then athletes can adjust their training regime to avoid more serious injury."
Marathon running causes extensive muscle damage, known as exercise-induced muscle damage (EIMD), which can impair performance and increase injury risk if recovery is incomplete. This study, published in the international peer-reviewed journal Physiological Reports, highlighted the ability of the OxiDx oxidative stress test as a novel diagnostic for monitoring this recovery. Levels of oxidative stress peaked 48 hours post-marathon and remained elevated for up to five days, correlating with traditional muscle damage indicators like reduced muscle force, increased soreness, and elevated creatine kinase.
Group data across the 20 participants indicated recovery by day six, however, individual variability was significant, with some runners showing prolonged recovery times. This variability emphasises the importance of individualised recovery monitoring to prevent premature training resumption. OxiDx's diagnostic sensitivity to recovery processes surpasses traditional markers by offering athletes and coaches a novel reliable tool for optimising post-marathon recovery and enhancing performance.
The world-first, patented OxiDx technology measures levels of muscle damage using a simple finger-prick blood sample to detect protein biomarkers in the blood. There is no equivalent test on the market. This successful study is a significant milestone in the commercialisation of the OxiDx test which is targeted for an Australian launch in H1 CY25.
About OxiDx
OxiDx Pty Ltd (Perth, Western Australia) is a 66 per cent owned subsidiary of Proteomics International.
OxiDx is commercialising technology for measuring oxidative stress developed in collaboration with The University of Western Australia. OxiDx uses next generation diagnostics technology, moving beyond measuring protein concentrations to detect subtle changes in protein structures known as posttranslational modifications or 'decorations' that reside on the surface of a protein. The patented OxiDx platform technology measures systemic oxidative stress in a fingerpick blood sample by using a sensitive ratiometric method to detect protein biomarkers in the blood. Samples can be collected in the home, clinic or on the field with high specificity to provide a comprehensive solution for monitoring oxidative stress levels.
Oxidative stress is implicated in over 70 health conditions with a person's levels often reflective of health and fitness. The ability to measure oxidative stress has broad application across multiple markets, from an athletic monitoring tool for competition preparedness and injury reduction in professional sports and horse racing industries, to a monitoring tool for health and wellbeing, including in primary industries such as stock production. It could also serve as a complementary diagnostic (CDx) test for assessing treatment efficacy and precision medicine by enabling personalised dosing in clinical trials.
*To view the Summary of Study, please visit:
https://abnnewswire.net/lnk/1WMJ4XK9
About Proteomics International Laboratories Ltd:
Proteomics International Laboratories (ASX:PIQ) is a wholly owned subsidiary and trading name of PILL, a medical technology company at the forefront of predictive diagnostics and bioanalytical services. The Company specialises in the area of proteomics - the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.
Source:
Proteomics International Laboratories Ltd
Contact:
Dr Richard Lipscombe Managing Director Proteomics International Laboratories Ltd T: +61 8 9389 1992 E: [email protected] Dirk van Dissel Investor Relations & Corporate Advisor Candour Advisory T: +61 408 326 367 E: [email protected] Proteomics International (Europe) Plesmanweg 9, 7602 PD Almelo The Netherlands T: +31 85 40 11 173 E: [email protected]
ABN Newswire
ABN Newswire is a business newswire and press release distribution service for listed companies on stock exchanges globally. ABN Newswire distributes company announcements to the professional platforms, finance portals and syndicates important corporate news to a wide variety of news aggregators and financial news systems.
